CTOs on the Move

Harken Health

www.harkenhealth.com

 
Harken Health is a new kind of health care company that unites relationship-based primary care with a range of competitively priced insurance plan options. Our care approach is rooted in the values of a simpler time when the doctor-patient relationship mattered. Harken Health Care Teams are empowered with the time to listen and build authentic, compassionate, trusting relationships with members. Our model enables us to remove many of the barriers that often get in the way of delivering exceptional care. Strong relationships and a home base for primary care have been shown to improve patient satisfaction and lower overall medical ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Peter Vladimirov
Chief Technology Officer Profile

Similar Companies

International Insurance Agency Services

International Insurance Agency Services, LLC is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Assisted Living of Pasco Inc

Assisted Living of Pasco Inc is a New Port Richey, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HMD Biomedical

HMD Biomedical is a Titusville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MediMedia, Inc

MediMedia, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Bruno, CA. To find more information about MediMedia, Inc, please visit www.medimedia.com

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.